TAK-755

Phase 3Biologic

Takeda

TAK-755 is one of 17 biologic programs targeting Acute Ischemic Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Ischemic StrokeRecruiting

Thrombotic Thrombocytopenic PurpuraCompleted

Acute Ischemic StrokePhase 2

Recruiting

Thrombotic Thrombocytopenic PurpuraPhase 3

Completed

Competition

Competitive Landscape

14 competitors in Acute Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

4 2

Actemra

CCelltrion

Phase 3

1 3

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

1 4

Rhtnk-Tpa

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Phase 3

1 5

TAK-755

Takeda

Phase 3

1 6

Cerebrolysin

EEver Neuro Pharma GmbH

Phase 2

1 7

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 2

1 8

Anisodine Hydrobromide

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

2 9

Prourokinase

SSuzhou Landing Pharmaceuticals

Phase 2

1 10

LT3001 Drug Product

LLumosa Therapeutics Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Thrombotic Thrombocytopenic Purpura

NCT04683003

Q4 2027

Phase 2Recruiting

Acute Ischemic Stroke

NCT07392450

Clinical

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura4 trials

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed·BBaxalta now part of Shire·Phase 3·NCT03393975·52 enrolled

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting· Takeda logo

Takeda·Phase 2·NCT05714969·33 enrolled

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Approved for marketing· Takeda logo

Takeda··NCT05770219

Show 1 more trial

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting· Takeda logo

Takeda·Phase 3·NCT04683003·77 enrolled

Sickle Cell Disease1 trial

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

Completed· Takeda logo

Takeda·Phase 1·NCT03997760·19 enrolled

Acute Ischemic Stroke1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

Recruiting· Takeda logo

Takeda·Phase 2·NCT07392450·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for TAK-755. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-755 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-755. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-755

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura4 trials

Sickle Cell Disease1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News